XNAS · Healthcare · Biotechnology
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.18 | -0.08 | +55.56% | $86,000 | ✅ Beat | +0.00% | +0.21% | -7.16% |
| 2026-02-27 | Q4 2025 | -0.19 | -0.12 | +36.84% | $130,000 | ✅ Beat | +2.71% | -0.88% | -2.07% |
| 2025-11-06 |
| Q3 2025 |
| -0.15 |
| -0.17 |
| -13.33% |
| $169,000 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-03-06 | Q4 2024 | -0.31 | -0.28 | +9.68% | $84,000 | ✅ Beat | -6.01% | -18.45% | -33.91% |
| 2024-11-07 | Q3 2024 | -0.23 | -0.29 | -26.09% | $121,000 | ❌ Miss | +0.16% | -9.98% | -12.84% |
| 2024-08-14 | Q2 2024 | -0.19 | -0.22 | -15.79% | $198,000 | ❌ Miss | +7.51% | +8.09% | +6.36% |
| 2024-02-29 | Q4 2023 | -0.50 | -0.18 | +64.00% | $76,000 | ✅ Beat | — | — | — |
| 2023-11-13 | Q3 2023 | -1.97 | -1.75 | +11.17% | $114,000 | ✅ Beat | +2.59% | +13.51% | -22.41% |
Showing last 8 quarters.